BMS BMY Future Plans BristolMyers Squibb posts 119 percent EPS beat on strong drug sales Market Recap Tech leads market gains while consumer sector trails United USEA Stock Risk Analysis Q4 2025 Earnings Fall Short GEN GENK Stock Risk Q4 2025 EPS Exceeds Expectations OGI Q1 2026 Earnings Narrowerthanexpected loss signals improving cost discipline KimberlyClark KMB Q1 2026 Earnings EPS Surpasses Estimates as Cost Discipline Lifts Profitability IN8bio Inc INAB Q1 2026 Earnings EPS Surprise of 63 Highlights Cost Discipline in PreRevenue Biotech VUZI Q1 2026 Earnings Narrowed Loss Surprises Revenue Remains Absent NVAX Q1 2026 Earnings NarrowerThanExpected Loss Beats Estimates Stock Edges Higher